MEDICENNA THERAPEUTICS CORP (MDNA)
CA58490H1073 - Common Stock
MDNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. MDNA has a great financial health rating, but its profitability evaluates not so good. MDNA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year MDNA has reported negative net income.
In the past year MDNA has reported a negative cash flow from operations.
MDNA had negative earnings in each of the past 5 years.
MDNA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of MDNA (-27.75%) is better than 73.60% of its industry peers.
With a decent Return On Equity value of -32.55%, MDNA is doing good in the industry, outperforming 79.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.75% | ||
| ROE | -32.55% | ||
| ROIC | N/A |
ROA(3y)-54.92%
ROA(5y)-55.46%
ROE(3y)-62.59%
ROE(5y)-78.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MDNA has more shares outstanding than it did 1 year ago.
MDNA has more shares outstanding than it did 5 years ago.
MDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
MDNA has an Altman-Z score of -2.42. This is a bad value and indicates that MDNA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.42, MDNA perfoms like the industry average, outperforming 48.84% of the companies in the same industry.
MDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.42 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
MDNA has a Current Ratio of 9.74. This indicates that MDNA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.74, MDNA is doing good in the industry, outperforming 72.44% of the companies in the same industry.
A Quick Ratio of 9.74 indicates that MDNA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.74, MDNA is doing good in the industry, outperforming 72.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.74 | ||
| Quick Ratio | 9.74 |
3. Growth
3.1 Past
MDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.76%, which is quite impressive.
EPS 1Y (TTM)56.76%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q42.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
MDNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.29% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-26.16%
EPS Next 2Y-24.06%
EPS Next 3Y-17.48%
EPS Next 5Y51.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MDNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDNA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as MDNA's earnings are expected to decrease with -17.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.06%
EPS Next 3Y-17.48%
5. Dividend
5.1 Amount
MDNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MEDICENNA THERAPEUTICS CORP
NASDAQ:MDNA (11/1/2023, 8:00:01 PM)
After market: 0.1565 0 (-0.32%)0.157
-0.02 (-13.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.93M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.75% | ||
| ROE | -32.55% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.74 | ||
| Quick Ratio | 9.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)56.76%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-26.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y